Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012)

Bibliography

• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31:986-1000
   PubMed Web of Science ®Google Scholar
• Woodward DF, Jones RL, Narumiya S; International Union Of Basic And Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011;63:471-538
   PubMed Web of Science ®Google Scholar
• Cathcart M, O'Byrne KJ, Reynolds JV, COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. Biochim Biophys Acta Rev Cancer 2012;1825:49-63
   PubMed Web of Science ®Google Scholar
• Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006;66:9794-7
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Watanabe R, Roles of prostaglandin E2 in cardiovascular diseases. Int Heart J 2011;52:266-9
   PubMed Web of Science ®Google Scholar
• Honda T, Tokura Y, Miyachi Y, Kabashima K. Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology. Curr Drug Targets 2010;11:1605-13
   PubMed Web of Science ®Google Scholar
• Kuwano K, Hashino A, Asaki T, 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322:1181-8
   PubMed Web of Science ®Google Scholar
• Allergan, Inc. Woodward DF, Martos JL, Wang JW, Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response. WO2012/3414 A1; 2012
   Google Scholar
• Allergan, Inc. Martos JL, Carling WR, Woodward DF, Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response. WO2012/024559;2012
   Google Scholar
• The Board Of Trustees Of The University Of Illinois. Carley D, Radulovacki M. Pharmacological treatments for sleep disorders. WO2007/047372A2; 2007
   Google Scholar
• Astellas Pharma, Inc. Sulfonamide compound or salt thereof. EP2050446; 2009
   Google Scholar
• Astellas Pharma, Inc. Sulfonamide compound or salt thereof. EP2305641; 2011
   Google Scholar
• Ono Pharmaceutical Co., Ltd. N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same. EP1369419; 2003
   Google Scholar
• Glaxo Group, Ltd. Phenyl compounds and their use in the treatment of conditions mediated by the action of PGE2 at the EP1 receptor. WO2005/108369; 2005
   Google Scholar
• Glaxo Group, Ltd. Benzofuran compounds as EP1 receptor antagonists. WO2007/113289; 2007
   Google Scholar
• Glaxo Group, Ltd. Indole compounds having affinity to the EP1 receptor. WO2008/6794; 2008
   Google Scholar
• Merck & Co. Carl FJ, Metters KM, Broten TP, Tuner M. Method of treating or preventing urinary incontinence using prostanoid EP1 receptor antagonists. US2002/137746; 2002
   Google Scholar
• Biotechnology Research Corp, Ltd. Ip NY, Ip FC, Hu Y. Triterpenoid compounds and methods of use thereof. WO2010/32123; 2010
   Google Scholar
• Asahi Kasei Pharma Corp. Bicyclic nitrogen-containing heterocyclic compounds. US2010/29733; 2010
   Google Scholar
• Asahi Kasei Pharma Corp. Nitrogen-containing heterocyclic compounds. US2010/29690; 2010
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedies for depression containing EP1 antagonist as the active ingredient. EP1369129; 2003
   Google Scholar
• Ono pharmaceutical Co., Ltd. Remedies for urinary frequency. EP1447096; 2004
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedies for post-traumatic stress disorder. EP1374899; 2004
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedy for urinary tract diseases. EP1642594; 2006
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder. EP2123273; 2009
   Google Scholar
• GlaxoSmithKline. Bountra C, Clayton NM, Naylor A. Formulations of adenosine A1 agonists. US2002/198170; 2002
   Google Scholar
• University Of Rochester. O'Keefe R, Zhang M, Schwarz EM. EP1 inhibition. WO2011/109729; 2011
   Google Scholar
• Astrazeneca AB. Method of treatment. WO2002/72098; 2002
   Google Scholar
• AstraZeneca AB. Method of treating a peripheral neuropathic pain. US6537991; 2003
   Google Scholar
• National University Co. Hamamatsu Univer. School of Medicine. Immunopotentiating agent comprising EP1 agonist. US2011/38884; 2011
   Google Scholar
• Pfizer, Inc. Treatment of BPH. US2005/20646; 2005
   Google Scholar
• The Johns Hopkins University. A method for the prevention and/or treatment of neurodegenerative diseases characterized by administering an EP1 receptor antagonist. WO2006/135545; 2006
   Google Scholar
• Alcon Manufacturing, Ltd. Prostaglandin E receptor agonists for treatment of dry eye. US6462080; 2002
   Google Scholar
• Alcon Manufacturing, Ltd. Prostaglandin E agonists for treatment of glaucoma. US6545045; 2002
   Google Scholar
• Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res 2011;36:809-17
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype selective prostaglandin E2 agonists. US6426359; 2002
   Google Scholar
• Pfizer Products, Inc. Use of EP2 selective receptor agonists in medical treatment. WO2004/78169; 2004
   Google Scholar
• Pfizer Products, Inc. EP2 agonists. WO2008/15517; 2008
   Google Scholar
• Pfizer, Inc. Cameron KO, Krauss AH, Lefker BA, EP2/4 agonists. WO2010/116270; 2010
   Google Scholar
• Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists. US6376533; 2002
   Google Scholar
• Allergan, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists. US2003/130239; 2003
   Google Scholar
• Allergan, Inc. 12-Aryl prostaglandin analogs. WO2006/63179; 2006
   Google Scholar
• Allergan, Inc. EP2 receptor agonists for treating glaucoma. US2007/49625; 2007
   Google Scholar
• Allergan, Inc. Woodward DF, Wang JW. EP2 receptor agonist from non-prostanoid structures designed as PGE2 antagonists. WO2010/135404; 2010
   Google Scholar
• Ono Pharmaceutical Co., Ltd. 8-Azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient. EP1481976; 2004
   Google Scholar
• Pharmagene Laboratories, Ltd. EP2 receptor agonists. WO2005/80367; 2005
   Google Scholar
• Pharmagene Laboratories, Ltd. EP2 receptor agonists. WO2005/61449; 2005
   Google Scholar
• Asterand Uk, Ltd. Oxford AW, Davis RJ, Coleman RA, EP2 receptor agonists. WO2007/17687; 2007
   Google Scholar
• Ube Industries, Ltd. Pyridylaminoacetic acid compound. EP2264009; 2010
   Google Scholar
• Schering Aktiengesellschaft. Fluorenes and carbazoles as ligands of the EP2 receptor. WO2007/71456; 2007
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Aryl/hetarylamides as modulators of the EP2 receptor. WO2008/152099; 2008
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Cinnamic acid derivatives as modulators of the EP2 receptor. WO2008/152097; 2008
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Substituted acetamides as modulators of the EP2 receptor. WO2008/152094; 2008
   Google Scholar
• Bayer schering pharma aktiengesellschaft. Diaminopyrimidines as modulators of the EP2 receptor. WO2008/152093; 2008
   Google Scholar
• Bayer Schering Pharma AG. Use of aryl and hetaryl amide derivatives as modulators of an EP2 receptor. EP2002838; 2008
   Google Scholar
• Bayer schering pharma aktiengesellschaft. N-(1-hetarylpiperidin-4-yl)(het)arylamides as EP2 receptor modulators. WO2008/28691; 2008
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor. WO2008/28690; 2008
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. N-(1-phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators. WO2008/28689; 2008
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Thienopyrimidylamines as modulators of the EP2 receptor. WO2009/7422; 2009
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Indolylalkylthienopyrimidylamines as modulators of the EP2 receptor. WO2009/7421; 2009
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Use of cinnamic acid derivatives as modulators of an EP2 receptor. EP2014287; 2009
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. Indolyamides as modulators for an EP2 receptor. EP2149554; 2010
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. 5,6 Substituted benzamide derivatives as modulators of EP2 receptors. EP2149552; 2010
   Google Scholar
• Bayer Schering Pharma AG. Extended benzamide derivatives as modulators of the EP2 receptor. US2010/29598; 2010
   Google Scholar
• Pfizer, Inc. Azetidines. US2008/280877; 2008
   Google Scholar
• Pfizer, Ltd. Skerratt SE. Azetidines as EP2 antagonists. WO2009/63365; 2009
   Google Scholar
• Pfizer. Dack KN, Mills JE, Skerratt SE. Pyrrolidines. US2010/120793; 2010
   Google Scholar
• Ligand pharmaceuticals, Inc. Letourneau JJ, Floyd DM, Ho K, Fused azabicyclic pyridines. WO2010/8777; 2010
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedy for spinal canal stenosis. EP1609480;2005
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters. EP1563846; 2005
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases. EP1661580; 2006
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Medicinal composition for inhalation. EP1806148; 2007
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Agent for regeneration and/or protection of nerves. EP1886693; 2008
   Google Scholar
• Synphora AB. Method and composition for treatment of erectile dysfunction. US6476074; 2002
   Google Scholar
• Pfizer. Thompson DD. Pharmaceutical compositions and methods for administering EP2 receptor selective agonists. US2003/166631; 2003
   Google Scholar
• Pfizer, Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist. US2005/65133; 2005
   Google Scholar
• The Texas A&M University System. Inhibition of prostglandin E2 receptors for the treatment of endometriosis. US2010/249125; 2010
   Google Scholar
• Schering AG. Method for fertility control. US2004/58975; 2004
   Google Scholar
• Bayer Schering Pharma Aktiengesellschaft. EP2 and EP4 agonists as agents for the treatment of influenza a viral infection. WO2008/58766; 2008
   Google Scholar
• Allergan, Inc. Compositions and methods for treating corneal haze. US2012/46332; 2012
   Google Scholar
• Sales, Kurt Jason; Jabbour, Henry Nicolas; Katz, Arieh. Method of treating a disease. US2003/220266; 2003
   Google Scholar
• Jabbour, Henry Nicolas. Methods of treatment of uterine pathological conditions. US2003/100591; 2003
   Google Scholar
• Medical research council. Use of an EP2 or EP4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer. WO2003/37373; 2003
   Google Scholar
• Medical research council. Antagonists of prostaglandin receptors EP2 and/or EP4 for the treatment of dysmenorrhea and menorrhagia. WO2003/37348; 2003
   Google Scholar
• The Board of Trustees of the Leland Stanford Junior University. Treatment of ischemic episodes and cerebroprotection through prostaglandin E2 (PGE2) EP2 and/or EP4 receptor agonists. US2010/267826; 2010
   Google Scholar
• Montine, Thomas J.; Shie, Feng-Shiun. Methods and compositions for the treatment of neurological diseases and disorders. US2007/232556; 2007
   Google Scholar
• Stjernschantz, Johan. Method for the treatment of glaucoma and ocular hypertension with prostaglandin analogues without melanogenic side effect. US2005/54723; 2005
   Google Scholar
• Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio. Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient. US2003/216381; 2003
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Benzoic acid derivatives and drugs containing the same as the active ingredient. EP1314719; 2003
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient. EP1431267; 2004
   Google Scholar
• Ono pharmaceutical Co., Ltd. Carboxylic acid compounds. EP1591441; 2005
   Google Scholar
• Pfizer, Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists. WO2005/021508; 2005
   Google Scholar
• Ono pharmaceutical Co., Ltd. Remedies for pruritus. EP1426059; 2004
   Google Scholar
• Ono pharmaceutical Co, Narumiya, Shuh. Narumiya S. Remedies for allergic diseases. EP1563845; 2005
   Google Scholar
• Ono pharmaceutical Co., Ltd. Therapeutic agent for psychoneurotic disease. EP1787657; 2007
   Google Scholar
• Bayer Healthcare AG. Diagnostics and therapeutics for diseases associated with G-protein coupled receptor prostaglandin E2 EP3 II (prostaglandin E2 EP3 II). WO2004/75813; 2004
   Google Scholar
• Bayer Healthcare AG. Diagnostics and therapeutics for diseases associated with G-protein coupled receptor prostaglandin E2 EP3 I (prostaglandin E2 EP3 I). WO2004/75814; 2004
   Google Scholar
• GlaxoSmithKline. Chissoe S. Genes associated with type II diabetes mellitus. US2008/200568; 2008
   Google Scholar
• The Johns Hopkins University. Antagonists of PGE2 EP3 receptors. WO2008/67532; 2008
   Google Scholar
• Maubach KA, Davis RJ, Clark DE, BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 2009;156:316-27
   PubMed Web of Science ®Google Scholar
• Antonova M, Wienecke T, Maubach K, The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain 2011;12:551-9
   PubMed Web of Science ®Google Scholar
• Ohta C, Kuwabe S, Shiraishi T, An improved synthesis of the selective EP4 receptor agonist ONO-4819. J Org Chem 2009;74:8298-308
   Google Scholar
• Nakase H, Fujiyama Y, Oshitani N, Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis 2010;16:731-3
   Google Scholar
• Glaxo Group, Ltd. Benzo[f]isoindole derivatives with affinity to the EP4 receptor. WO2002/64564; 2002
   Google Scholar
• Glaxo Group, Ltd. Benzoisoindole derivatives and their use as EP4 receptor ligands. WO2007/93578; 2007
   Google Scholar
• Glaxo Group, Ltd. Benzoisoindole derivatives and their use as EP4 receptor agonists. WO2008/61955; 2008
   Google Scholar
• Glaxo Group, Ltd. Isoindol derivatives as EP4 receptor agonists. WO2008/46798; 2008
   Google Scholar
• Glaxo Group, Ltd. Benzo [F] isoindoles as EP4 receptor agonists. WO2008/12347; 2008
   Google Scholar
• Glaxo Group, Ltd. Naphthalene derivatives used as EP4 receptor agonists. WO2008/12344; 2008
   Google Scholar
• Glaxo Group, Ltd. Novel isoindol derivatives as EP4 receptor agonists. WO2008/20055; 2008
   Google Scholar
• Glaxo Group, Ltd. Benzoisoindole derivatives and their use as EP4 receptor agonists for the treatment of pain. WO2009/19281; 2009
   Google Scholar
• Glaxo Group, Ltd. Benzoisoindole derivatives and their use as EP4 receptor agonists for the treatment of pain. WO2009/19281; 2009
   Google Scholar
• Glaxo Group, Ltd. Novel isoindol derivatives as EP4 receptor agonists. WO2008/20055; 2008
   Google Scholar
• Glaxo Group, Ltd. Benzamide derivatives as EP4 receptor agonists. WO2008/71736; 2008
   Google Scholar
• Glaxo Group, Ltd. Novel EP4 receptor agonist compounds. WO2009/147165; 2009
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having EP sb 4/sb agonist as the active ingredient. EP1417975; 2004
   Google Scholar
• Ono Pharmaceutical Co., Ltd. 8-Azaprostaglandin derivatives and medicinal uses thereof. EP1586564; 2005
   Google Scholar
• Applied Research Systems Ars Holding N.V. Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors. WO2003/35064; 2003
   Google Scholar
• Pfizer, Inc. Cameron KO, Lefker BA. EP4 receptor selective agonists in the treatment of osteoporosis. US2002/65308; 2002
   Google Scholar
• Pfizer, Inc. Cameron KO, Lefker BA, Knight DR. Methods of treatment with selective EP4 receptor agonists. US2003/207925; 2003
   Google Scholar
• Pfizer, Inc. Cameron KO, Lefker BA. Use of selective EP4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension. US2003/176479; 2003
   Google Scholar
• Merck Frosst Canada and Co. Billot X, Young R. 1,5-Disubstituted imidazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of eye and bone diseases. WO2003/103664; 2003
   Google Scholar
• Merck and Co., Inc. Merck Frosst Canada and Co. Method for treating ocular hypertension. WO2003/47513; 2003
   Google Scholar
• Merck and Co., Inc.; Merck Frosst Canada and Co. EP4 receptor agonist, compositions and methods thereof. WO2003/47417; 2003
   Google Scholar
• Merck & Co. Ogidigben MJ, Young RN, Metters KM, Slipetz DM. Ep4 receptor agonist, compositions and methods thereof. US2004/204590; 2004
   Google Scholar
• Merck Frosst Canada and Co. 1,5-Distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the teatment of eye diseases such as glaucoma. WO2003/103772; 2003
   Google Scholar
• Merck Frosst Canada and Co., Beunard, Jean-Luc; Colucci, John. Beunard J, Colucci J. Pyrrolidin-2-on derivatives as EP4 receptor agonists. WO2004/37813; 2004
   Google Scholar
• Merck Frosst Canada and Co. EP4 receptor agonists. WO2004/37786; 2004
   Google Scholar
• Merck Frosst Canada and Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma. WO2004/19938; 2004
   Google Scholar
• Merck & Co. Billot X, Colucci J, Han Y, EP4 receptor agonist, compositions and methods thereof. US2004/198701; 2004
   Google Scholar
• Merck and Co., Inc. Process for making EP4 agonists and intermediates thereof. WO2005/79337; 2005
   Google Scholar
• Merck Frosst Canada, Ltd. EP4 receptor agonist, compositions and methods thereof. WO2007/14462; 2007
   Google Scholar
• Merck Frosst Canada, Ltd. EP4 receptor agonist, compositions and methods thereof. WO2007/14454; 2007
   Google Scholar
• Merck Frosst Canada & Co. Quinolinones as prostaglandin receptor ligands. WO03/051878; 2003
   Google Scholar
• Merck Frosst Canada, Ltd. EP4 receptor agonist, compositions and methods thereof. WO2005/116010; 2005
   Google Scholar
• Roche. Elworthy TR, Mirzadegan T, Roepel MG, 8-Aza-11-deoxy prostaglandin analogues. US2003/120079; 2003
   Google Scholar
• Roche. Elworthy TR, Roepel MG, Smith DB. 2-pyrrolidone derivatives as prostanoid agonists. US2003/64964; 2003
   Google Scholar
• Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists. US2005/228185; 2005
   Google Scholar
• Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists. US2005/49227; 2005
   Google Scholar
• Allergan, Inc. Substituted pyrrolidone compounds as EP4 agonists. WO2006/52893; 2006
   Google Scholar
• Allergan, Inc. Therapeutic substituted piperidone compounds. WO2006/52630; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. Bicyclic derivatives as EP4 agonists. WO2008/92862; 2008
   Google Scholar
• Janssen Pharmaceutica N.V. Bicyclic derivatives as EP4 agonists. WO2008/92861; 2008
   Google Scholar
• Janssen Pharmaceutica N.V. Bicyclic derivatives as EP4 agonists. WO2008/92860; 2008
   Google Scholar
• Astellas Pharma, Inc. Pyridone compound. EP2154130; 2010
   Google Scholar
• Astellas Pharma, Inc. Pyridone compound. EP2301922; 2011
   Google Scholar
• Astellas Pharma, Inc. Ornithine derivative. EP2141147; 2010
   Google Scholar
• Asahi Glass Co., Ltd. Kaken Pharmaceutical Co., Ltd. Novel EP4 agonist. US2011/98481; 2011
   Google Scholar
• Glaxo Group, Ltd. Benzo(F) isoindol derivatives and their use as EP4 receptor ligands. WO2002/50033; 2002
   Google Scholar
• Glaxo Group, Ltd. Naphthalene derivatives which bind to the EP4 receptor. WO2002/50032; 2002
   Google Scholar
• Glaxo Group, Ltd. Indole derivatives. WO2002/50031; 2002
   Google Scholar
• Glaxo Group, Ltd. Benzo[f]isoindole derivatives with affinity to the EP4 receptor. WO2002/64564; 2002
   Google Scholar
• Merck Frosst Canada, Ltd. Quinoline derivatives as EP4 antagonists. WO2006/122403; 2006
   Google Scholar
• Merck Frosst Canada, Ltd. Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists. WO2008/116304; 2008
   Google Scholar
• Merck Frosst Canada, Ltd. Indoline amide derivatives as EP4 receptor ligands. WO2007/143825; 2007
   Google Scholar
• Merck Frosst Canada, Ltd. Indole amide derivatives as EP4 receptor antagonists. WO2007/121578; 2007
   Google Scholar
• Merck Frosst Canada, Ltd. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists. WO2008/104055; 2008
   Google Scholar
• Merck Frosst Canada, Ltd. Molinaro C, Nadeau C, Hughes G. Process for making indole cyclopropyl amide derivatives. WO2010/121382; 2010
   Google Scholar
• Merck and CO., Inc. Merck Frosst Canada, Ltd. Process for making thiophene carboxamide derivative. WO2009/20588; 2009
   Google Scholar
• Merck Frosst Canada, Ltd. Berthelette C, Boyd M, Burch J, Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists. WO2010/34110; 2010
   Google Scholar
• Theratechnologies, Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4. WO2003/99857; 2003
   Google Scholar
• Pfizer, Inc. Audoly L, Okumura T, Shimojo M. EP4 receptor inhibitors to treat rheumatoid arthritis. US2002/77329; 2002
   Google Scholar
• Warner-Lambert. Shimojo M, Taniguchi K. Use of EP4 receptor ligands in the treatment of IL-6 involved diseases. US2003/236260; 2003
   Google Scholar
• Pfizer Pharmaceuticals, Inc. Pfizer, Inc. Use of EP4 receptor ligands in the treatment OF IL-6 involved diseases. WO2003/86371; 2003
   Google Scholar
• Pharmagene Laboratories, Ltd. EP4 receptor antagonists. WO2004/67524; 2004
   Google Scholar
• Pharmagene Laboratories, Ltd. Furan derivatives as EP4 receptor antagonists. WO2005/37812; 2005
   Google Scholar
• Allergan, Inc. Prostaglandin EP4 antagonist. US2005/65200; 2005
   Google Scholar
• Allergan, Inc. Prostaglandin EP4 antagonists. US2006/94742; 2006
   Google Scholar
• Astellas Pharma, Inc. Amide compound. EP2172447; 2010
   Google Scholar
• Astellas Pharma, Inc. Amide compound. EP2277858; 2011
   Google Scholar
• Chemietek LLC, Yuan WW. Heterocyclic amide derivatives as EP4 receptor antagonists. WO2010/19796; 2010
   Google Scholar
• Maruyama, Toru; Kobayashi, Kaoru. 5-Thia-omega-(substituted phenyl)-prostaglandin E alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the active ingredient. US2003/97023; 2003
   Google Scholar
• Ono Pharmaceutical Co., Ltd. 5-Thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient. US6462081; 2002
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass. US2004/209848; 2004
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist. EP1782830; 2007
   Google Scholar
• Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing EP4 agonist. EP1782829; 2007
   Google Scholar
• Nat. University Corp. Hamamatsu University School of Medicine; ONO Pharmaceutical Co., Ltd. Cytotoxic T cell activator comprising EP4 agonist. EP2147672; 2010
   Google Scholar
• Pharmagene Laboratories, Ltd. Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment. US2003/158240; 2003
   Google Scholar
• Glaxo Group, Ltd. Use of EP4 receptor agonists for treating neuropathic pain. WO2002/47669; 2002
   Google Scholar
• Pfizer Products, Inc. Combinations comprising alpha-2-delta ligands. WO2005/102389; 2005
   Google Scholar
• Pfizer Products, Inc. Continuous combination therapy with selective prostaglandin EP4, receptor agonists and an estrogen for the treatment of conditions that present with low bone mass. WO2005/60946; 2005
   Google Scholar
• Allergan, Inc. Therapeutic and delivery methods of prostaglandin z4 agonists. WO2006/47476; 2006
   Google Scholar
• Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components. US2007/123568; 2007
   Google Scholar
• Allergan, Inc. Methods and compositions for treating gastrointestinal disorders. WO2008/76703; 2008
   Google Scholar
• Simon Fraser University; Young, Robert N.; Arns, Stephen; Moreau, Anne; Morshad, Monzur; Gibe, Romelo. Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof. WO2011/147034; 2011
   Google Scholar
• Boehringer Ingelheim International GMBH. Nickolaus P. Combinations of medicaments, containing PDE4 inhibitors and EP4 receptor antagonists. WO2011/124525; 2011
   Google Scholar
• Bayer Healthcare AG. Diagnostics and therapeutics for diseases associated with G-protein coupled receptor prostaglandin E2 EP4 (Prostaglandin E2 EP4). WO2004/73589; 2004
   Google Scholar
• Raqualia Pharma, Inc. Kanazawa K, Nonomura K, Okumura T, Koizumi S. Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases. WO2011/102149; 2011
   Google Scholar
• RaQualia Pharma, Inc. Selective EP4 receptor agonistic substance for treatment of cancer. EP2422779; 2012
   Google Scholar
• Kumagai, Hiroki; Yamada, Naohiro; Hayashi, Ryoji; Mori, Takeshi; Isogaya, Masafumi. Hair growth or hair formation controlling agents. US2003/83381; 2003
   Google Scholar
• Gemmus Pharma, Inc. Guilford WJ, Faulds DH. Combination therapy treatment for viral infections. WO2011/47048; 2011
   Google Scholar